Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
Conditions:   Alport Syndrome;   Focal Segmental Glomerulosclerosis Intervention:   Drug: R3R01 Sponsors:   River 3 Renal Corp.;   IQVIA Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2022 Category: Research Source Type: clinical trials